Telix Pharmaceuticals to Acquire RLS (USA) to Expand North American Radiopharmacy Manufacturing and Distribution

Telix Pharmaceuticals to Acquire ITM Isotope Technologies Munich

September 21, 2026

Pharmaceuticals

Telix Pharmaceuticals signed an agreement to acquire 100% of ITM Isotope Technologies Munich for $1.65 billion upfront, plus up to $700 million in contingent payments tied primarily to regulatory approvals and sales milestones for ITM-11. The deal combines Telix’s radiopharmaceutical development and commercial platform with ITM’s isotope manufacturing, distribution network, and therapeutic pipeline; it remains subject to shareholder and regulatory approvals.

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals

April 24, 2026

Biotechnology

Telomir Pharmaceuticals completed its previously announced stock-for-stock acquisition of TELI Pharmaceuticals. The deal makes Telomir the sole holder of global rights to Telomir-1 (Telomir-Zn), consolidating worldwide development and commercialization under one structure.

LIXTE Biotechnology Acquires Liora Technologies Europe Ltd

November 25, 2025

Medical Devices

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has completed the acquisition of Liora Technologies Europe Ltd., a UK-based developer of the LiGHT proton therapy system. The deal brings Liora's proprietary LiGHT System and Daresbury-based operations into LIXTE as a wholly owned subsidiary to expand the company's capabilities into radiotherapy and pursue joint treatment-center revenue models.

Telix Pharmaceuticals Acquires ARTMS Inc.

March 5, 2024

Pharmaceuticals

Telix Pharmaceuticals Limited has completed the acquisition of ARTMS Inc., a Burnaby, British Columbia-based developer of cyclotron-based isotope production technology and the QUANTM Irradiation System (QIS). The deal strengthens Telix's vertical integration and supply-chain control for key diagnostic and therapeutic radioisotopes (including 89Zr, 68Ga, 99mTc and 64Cu) to support its commercial products and pipeline.

Telix Pharmaceuticals Acquires QSAM Biosciences

February 8, 2024

Biotechnology

Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc., adding QSAM's lead radiopharmaceutical candidate 153Sm-DOTMP (Samarium-153-DOTMP) to Telix's therapeutic pipeline. The asset expands Telix's oncology focus into bone-targeting radiopharmaceuticals with potential applications in pain management of bone metastases and osteosarcoma (including pediatric indications).

Warburg Pincus and Tilia Acquire FlexXray from Levine Leichtman Capital Partners

July 26, 2021

Food & Beverage

Warburg Pincus and Tilia Holdings have acquired FlexXray, a leading provider of x-ray inspection and recovery services for the food industry, from Levine Leichtman Capital Partners. The investment is intended to support FlexXray's growth and expansion of its food-safety inspection capabilities and geographic reach; financial terms were not disclosed.